View Document Preview and Link Document Date: 2014-08-12 13:02:43 Open Document File Size: 110,20 KB Share Result on Facebook
City Horsham / New York / / Company Pfizer Inc / Janssen Biotech Inc. / / Event Product Issues / Person Communication and Meetings / / Facility American College / American College of Gastroenterology / / IndustryTerm treatment of rheumatic diseases / / MedicalCondition human tumor necrosis / necrosis / tumour necrosis / disease / ankylosing spondylitis / rheumatic diseases / rheumatoid arthritis / pouchitis / Plaque Psoriasis / latent TB infection / moderate-to-severe ulcerative colitis / Ulcerative Colitis / inflammatory conditions / diseases / pathologic inflammation / early-onset rheumatoid arthritis / active rheumatoid arthritis / inflammation / inflammatory condition / psoriatic arthritis / / Organization European League Against Rheumatism / Food and Drug Administration / Practice Parameters Committee / the American College / American College of Rheumatology / American College of Gastroenterology / / Person Care Res (Hoboken) / Ann Rheum / / / Position physician / GO-FORWARD / / Product Humira / Orencia / Kineret / Enbrel / Rituxan / Simponi injection / Remicade / mercaptopurine / azathioprine / response / / Technology alpha / / SocialTag 
PRIOR AUTHORIZATION POLICY Simponi™ (golimumab for subcutaneous [SC] injection – Janssen Biotech, Inc.) To Initiate a Coverage Review, Call[removed]OVERVIEW Simponi SC is a recombinant human monoclonal antibod